New research spearheaded by scientists at the Seaver Autism Center for Research and Treatment at Mount Sinai indicates that Phelan-McDermid syndrome (PMS) could be considerably more common than earlier estimations suggested. The groundbreaking findings, recently published in the esteemed journal Autism Research, propose that the condition affects approximately 1 in 7,300 individuals. This revised prevalence estimate represents a substantial upward revision from previous figures, suggesting that tens of thousands of people in the United States may be living with PMS without a diagnosis.
Understanding Phelan-McDermid Syndrome: A Genetic Basis for Complex Challenges
Phelan-McDermid syndrome is a rare genetic disorder characterized by a deletion or mutation affecting the SHANK3 gene, located on chromosome 22. This genetic anomaly can manifest in a wide spectrum of medical, intellectual, and behavioral challenges. A significant hallmark of PMS is its strong association with autism spectrum disorder (ASD); indeed, a majority of individuals diagnosed with PMS also meet the diagnostic criteria for ASD. Scientific understanding has increasingly pointed to the SHANK3 gene as a critical factor, with alterations in this gene believed to be responsible for as many as one percent of all diagnosed cases of autism spectrum disorder.
The SHANK3 gene plays a crucial role in the development and function of synapses, the specialized junctions between nerve cells that enable communication in the brain. These synapses are fundamental for learning, memory, and overall cognitive and behavioral development. When SHANK3 is altered or absent, synaptic function can be impaired, leading to the diverse array of symptoms observed in individuals with PMS. These can include intellectual disability, developmental delays, speech and language impairments, hypotonia (low muscle tone), behavioral issues such as anxiety and repetitive behaviors, and a range of other physical and medical complications, such as gastrointestinal problems, sleep disturbances, and congenital anomalies.
The Power of Genetic Data: Unveiling a Larger Affected Population
The substantial revision in the estimated prevalence of Phelan-McDermid syndrome stems from a comprehensive analysis of extensive genetic data. The Mount Sinai research team collaborated with a network of leading genetic testing laboratories, prominent academic medical centers, and dedicated autism research programs. Their meticulous examination encompassed data from nearly 180,000 individuals who had undergone genetic testing, with a particular focus on those diagnosed with autism.
This extensive analysis was a synthesis of information drawn from ten distinct sources, including major commercial genetic testing providers like GeneDx, Labcorp, and Ambry Genetics, as well as large-scale research initiatives such as the SPARK (Simons Foundation Powering Autism Research for Knowledge) study and the Autism Sequencing Consortium. Furthermore, data from several major children’s hospitals contributed to the dataset, providing a broad and representative sample.
By carefully integrating these diverse data streams and employing sophisticated statistical methods, the researchers were able to account for several factors that might have previously led to underestimation. These included the presence of undiagnosed cases of PMS, limitations inherent in certain genetic testing methodologies that might not fully detect all SHANK3 variations, and individuals with PMS who do not present with overt symptoms that would lead to an autism diagnosis. After these crucial adjustments, the team arrived at a revised prevalence estimate of 13.7 cases per 100,000 people. This translates to approximately 1 individual in every 7,300 people.
This new estimate marks a significant departure from prior figures, which were often based on smaller, less comprehensive studies and anecdotal evidence. Previous estimates for PMS prevalence had varied widely, with some suggesting rates as low as 1 in 100,000. The current findings suggest that the actual number of individuals affected by PMS in the United States could exceed 45,000, a stark contrast to the number of individuals formally diagnosed.
Bridging the Diagnostic Gap: Barriers to Testing and Diagnosis
The significant disparity between the number of known cases and the newly estimated prevalence highlights critical challenges in the diagnostic pathway for Phelan-McDermid syndrome. Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the published paper, articulated the likely reasons for this diagnostic gap.
"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," stated Levy. "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."
This underscores a systemic issue where access to comprehensive genetic diagnostics can be uneven. For families navigating the complexities of developmental disorders, the recommendation and availability of specific genetic tests are paramount. Insurance coverage can be a significant hurdle, with policies sometimes not fully covering the cost of advanced genetic sequencing or diagnostic panels necessary to identify rare disorders like PMS. Furthermore, not all genetic tests are created equal. Some may focus on more common genetic mutations, potentially missing the subtler deletions or mutations within the SHANK3 gene that characterize PMS. This emphasizes the need for standardized diagnostic protocols and improved insurance coverage for genetic testing in individuals with unexplained developmental or neurological challenges.
The Imperative of Genetic Testing: Unlocking Treatment and Support
The researchers strongly advocate for expanded access to genetic testing as a crucial step in identifying individuals with PMS who currently lack a formal diagnosis. The knowledge gained from genetic testing offers profound benefits beyond simply understanding the cause of a person’s symptoms.
Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the paper, emphasized the transformative potential of genetic diagnosis. "We recommend that every child with autism undergo genetic testing, because knowledge is power," he asserted. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
The implications of a timely and accurate genetic diagnosis are far-reaching. For individuals with PMS and their families, it opens doors to a range of vital resources and opportunities. This includes access to specialized medical care tailored to the specific needs associated with the syndrome, enrollment in research studies that advance scientific understanding, participation in clinical trials for emerging therapies, and connection with supportive patient advocacy groups. Crucially, for those with PMS, a genetic diagnosis is becoming increasingly important as new therapeutic avenues are explored.
A Timeline of Discovery and Hope: Advancements in PMS Research
The current study represents one of the most comprehensive efforts to date to accurately estimate the prevalence of Phelan-McDermid syndrome. Its findings arrive at a pivotal moment for PMS research, coinciding with significant progress in the development of potential treatments. The research was notably supported by CureSHANK and Neuren Pharmaceuticals, organizations actively involved in advancing PMS research and therapeutic development.
Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, highlighted the ethical imperative driving this research. "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth stated. "Patients cannot benefit from these advances if they never receive a diagnosis."
This sentiment is echoed by Geraldine Bliss, Board Chair of CureSHANK, an organization dedicated to improving the lives of individuals with PMS through research, advocacy, and support. "This study confirms what many families, clinicians, and advocates have suspected for years," said Bliss. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
CureSHANK’s commitment to expanding access to genetic testing is further reinforced by initiatives like "Start Genetic," a global awareness campaign. This campaign aims to educate patients, families, healthcare providers, and advocacy groups about the importance of prioritizing genetic testing when encountering developmental or neurological concerns. The overarching message is clear: the promise of precision medicine, with its tailored and targeted therapies, can only be fully realized if patients are first identified and accurately diagnosed.
The Dawn of New Treatments: Precision Medicine for PMS
The burgeoning field of precision medicine is bringing renewed hope to the Phelan-McDermid syndrome community. Several promising clinical trials are currently underway, exploring innovative approaches that directly target the underlying biological mechanisms of the disorder. These trials are a direct result of the scientific insights gained from understanding the genetic basis of PMS, particularly the role of the SHANK3 gene.
The development of these targeted therapies represents a paradigm shift in how rare genetic disorders are treated. Instead of a one-size-fits-all approach, precision medicine aims to develop interventions that are specific to the genetic defect responsible for the condition. For PMS, this could mean therapies designed to restore or enhance the function of the SHANK3 protein, or to compensate for its absence or malfunction.
The potential impact of these advancements on individuals with PMS is profound. A genetic diagnosis, once primarily a tool for understanding, is now evolving into a gateway for accessing cutting-edge treatments that could significantly improve quality of life, mitigate developmental challenges, and potentially alter the course of the disorder. This underscores the critical importance of the current research and the ongoing efforts to identify every individual who could benefit from these emerging therapeutic interventions. The journey from genetic discovery to clinical application is complex and often lengthy, but the progress in PMS research signifies a tangible path towards improved outcomes for those affected by this syndrome.
